TPST Projected Dividend Yield
Tempest Therapeutics Inc ( NASDAQ : TPST )Tempest Therapeutics is a biopharmaceutical company, focused on developing treatments for endocrine diseases. Co.'s three product candidates are: Livoletide (AZP-531), which is for the treatment Prader-Willi syndrome, a genetic endocrine disease usually characterized by hyperphagia, or insatiable hunger; nevanimibe (ATR-101), which is a potential treatment for patients with congenital adrenal hyperplasia, a monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses; and NK3R antagonist (MLE-301), which is a potential treatment of vasomotor symptoms commonly known as hot flashes and night sweats, in menopausal women. 20 YEAR PERFORMANCE RESULTS |
TPST Dividend History Detail TPST Dividend News TPST Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |